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Abstract
Background: Cell-free tumor-derived DNA (ctDNA) allows non-invasive monitoring of cancers, but its utility in renal
cell cancer (RCC) has not been established.
Methods: Here, a combination of untargeted and targeted sequencing methods, applied to two independent cohorts
of patients (n = 91) with various renal tumor subtypes, were used to determine ctDNA content in plasma and urine.
Results: Our data revealed lower plasma ctDNA levels in RCC relative to other cancers of similar size and stage, with
untargeted detection in 27.5% of patients from both cohorts. A sensitive personalized approach, applied to plasma and
urine from select patients (n = 22) improved detection to ~ 50%, including in patients with early-stage disease and
even benign lesions. Detection in plasma, but not urine, was more frequent amongst patients with larger tumors and
in those patients with venous tumor thrombus.
With data from one extensively characterized patient, we observed that plasma and, for the first time, urine ctDNA may
better represent tumor heterogeneity than a single tissue biopsy. Furthermore, in a subset of patients (n= 16), longitudinal
sampling revealed that ctDNA can track disease course and may pre-empt radiological identification of minimal residual
disease or disease progression on systemic therapy. Additional datasets will be required to validate these findings.
Conclusions: These data highlight RCC as a ctDNA-low malignancy. The biological reasons for this are yet to be
determined. Nonetheless, our findings indicate potential clinical utility in the management of patients with renal tumors,
provided improvement in isolation and detection approaches.
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Background
Renal cell carcinoma (RCC) is the most lethal urological
malignancy with 50% of patients that develop the disease
dying from it [1]. Clinical management challenges in-
clude the following: early diagnosis; differentiation of
histological subtypes, i.e., chromophobe RCC (chRCC)
from clear cell RCC (ccRCC) or benign oncocytoma;
identification of patients with minimal residual disease
following intended curative nephrectomy which will
allow improved stratification of patients for adjuvant
therapy trials; and predicting and tracking of response to
targeted therapies. RCC has well-established pathological
and genetic heterogeneity [2], which confounds develop-
ment of personalized medicine [3]. Moreover, ccRCC
exhibits a broad range of metastatic phenotypes [4]
highlighting the need for longitudinal sampling. Due to
the invasive nature of the procedure and failure to cap-
ture genetic heterogeneity, tissue biopsies potentially
inadequately inform treatment decisions [5]. A “liquid
biopsy,” providing an admixture of the entire tumor bur-
den of a patient, may offer a non-invasive alternative to
traditional tumor sampling techniques. Cell-free DNA
(cfDNA), which in patients with cancer contains cell-
free tumor-derived DNA (ctDNA), represent one such
promising liquid biopsy strategy [6–8].
Despite showing great promise in various cancers [6],
there is little and often contradictory data of ctDNA as a
tool in RCC in locally advanced and metastatic RCC [6, 9,
10]. As such, there remains an unmet need for the
characterization of the levels, and potential clinical utility,
of ctDNA in renal cancers of differing stage and subtype
[11, 12]. Furthermore, while evidence suggests ctDNA in
the urine can be informative in urological cancers [13, 14],
no previous study has assessed the presence of ctDNA in
the urine of RCC patients. Here we aimed to determine
the presence, levels, heterogeneity, and potential clinical
applications of ctDNA in plasma and urine of 91 patients
with renal tumors ranging from benign oncocytomas
through to metastatic RCCs using both untargeted
genome-wide and targeted sequencing approaches.
Methods
DIAMOND study sample collection
Patients with a range of renal malignancies were recruited
to the DIAMOND study according to the local ethical
guidelines (REC ID 03/018). Patient characteristics and
renal tumor pathological details are presented in Fig. 1a, b
and Additional file 1: Table S1.
Patients underwent partial or total nephrectomy as
part of curative treatment or cytoreductive surgery.
Tumor tissue, from 29 patients, was obtained during
these procedures and samples were stored as either fresh
frozen (FF) or formalin fixed paraffin-embedded (FFPE)
specimens. An average of four spatially separate tumor
regions per patient (range 2 to 10 regions, 128 across all
patients) were obtained, in order to study and overcome
tumor heterogeneity prevalent in renal cancer [2].
For FF samples, a small piece of tissue weighing < 20mg
was removed and DNA was extracted using a DNeasy
Blood & Tissue kit (QIAGEN) according to the manufac-
turer’s protocol. For the FFPE samples, 2-mm-diameter
and 3-mm3-deep cores were obtained and DNA was ex-
tracted using the GeneRead DNA FFPE kit (QIAGEN) ac-
cording to the manufacturer’s protocol, apart from the
56 °C incubation step which was carried out overnight in-
stead of for 1 h. This protocol utilizes uracil-N-glycosy-
lases enzymes in order to remove artifacts resulting from
the deamination of cytosine during the fixation process.
All extracted DNA was quantified using the Qubit assay
run on the PheraStar FSX platform (BMG LabTech).
From all DIAMOND patients, we collected blood
plasma prior to surgery (mean 5.0, range 0–35 days
pre-surgery) and samples were processed as follows.
For samples collected prior to April 2016 (21/32 pa-
tients), 8 ml of blood was collected into EDTA tubes
and, within 1 h, centrifuged at room temperature at
4000 rpm for 20 min. The plasma layer was subse-
quently decanted into separate cryotubes. The buffy
coat layer was transferred into a sterile 2-ml microfuge
tube for parallel use. For samples collected after April
2016 (11/32 patients), 12 ml of blood was collected into
EDTA tubes and centrifuged at room temperature at
1600g for 10 min within an hour of collection. Avoiding
the buffy coat layer, 4 ml of plasma was transferred to
RNase-free microfuge tubes and spun on a bench top
centrifuge at 13,300 rpm for 10 min. The supernatant
was transferred to a 2-ml sterile microfuge tube and
the pellet was discarded. The buffy coat layer was trans-
ferred from the original collection tube into a sterile 2-
ml microfuge tube for parallel use. Once processed, all
samples were stored at − 80 °C.
For 37 patients, urine samples were also collected
prior to surgery (mean 8.9, range 0–35 days pre-
surgery). For 15 patients, we isolated only urine super-
natant (USN) while for the 22 remaining samples, we
isolated both USN and urine cell pellet (UCP), as fol-
lows. From each patient, 30–50 ml urine was collected
in a 50-ml falcon tube, and 0.5 M EDTA was added
within an hour of collection (pH 8.0; 600 μl for 30 ml,
final concentration 10mM. For larger volumes of urine,
the volume of EDTA was adjusted accordingly). After
gentle inversion, the sample was spun at 2400g for 10
min. Subsequently, ~ 3.6 ml of supernatant was trans-
ferred into a separate cryotube. For UCP collection, an
additional 1 ml of supernatant was transferred to a
separate microfuge tube, while the remaining super-
natant was discarded. The 1 ml supernatant was then
returned to the original falcon tube containing the UCP.
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This was agitated and the remaining liquid was trans-
ferred to a sterile 2-ml microfuge tube. This was spun at
13,300 rpm for 10 min and the supernatant was dis-
carded leaving a dry UCP for storage at − 80 °C.
As well as pre-surgery plasma and urine, from a subset
of patients we also collected post-surgery plasma and
urine (Additional file 1: Fig. S1). Furthermore, in addition
to renal cancer patient samples, we obtained plasma (Sera
Fig. 1 Study design, patient characteristics, and tumor genomic profile. a ctDNA analysis in RCC patients was applied to two patient cohorts,
DIAMOND and MonReC. Initially, untargeted sequencing methods were applied to samples. For DIAMOND, tMAD analysis of sWGS data was
applied. For MonReC, a combination of z-score analyses of mFAST-SeqS data and ichorCNA analysis of sWGS data was applied. Subsequently,
targeted sequencing methods were used. For DIAMOND, INVAR-TAPAS was applied to patient plasma (n = 29) and urine (n = 20). For MonReC, a
QIASeq custom capture panel targeting the 10 most commonly mutated genes in RCC patients was applied. b For DIAMOND, plasma (n = 48)
and urine (n = 37) were collected from patients with a range of tumor subtypes and stages. Specifically, 29 ccRCCs (11/1/16 stage I, II, and III
respectively), 7 chRCCs (2/2/3 stage I, II, and III), 8 oncocytomas, 1 patient with papillary RCC (stage III), 1 patient with a MiT family translocation
RCC (stage II), and 2 patients with oncocytic renal neoplasm. Shown, in descending order, are tumor tissue mutation status of frequently mutated
RCC genes (pale blue cubes indicate that a mutation was detected, white space indicates that no mutation was detected, gray columns indicate
that tissue was not available for that patient), tumor subtype, tumor size, tumor stage, metastatic at baseline, evidence of venous tumor
thrombus, and number of tumor SNVs (targeted for INVAR-TAPAS). c For MonReC, plasma (n = 43) was collected from 41 patients with metastatic
RCC and two with localized RCC. Shown, in descending order, are plasma mutation status (after QIASeq, blue, medium blue and dark blue cubes
indicate that a mutation was detected at baseline, during follow-up, or at both time points respectively) of frequently mutated RCC genes, tumor
subtype, tumor size, and metastatic at time of sampling. More comprehensive versions of b and c are provided in Additional file 1: Fig. S15
Smith et al. Genome Medicine           (2020) 12:23 Page 3 of 17
Labs) and urine DNA (local collection) from healthy indi-
viduals to act as controls for mutation analysis.
DNA was extracted from the fluid samples, as well as
matched buffy coat samples, using the QIAsymphony
platform (QIAGEN). DNA was quantified using the
Qubit assay on the PheraStar FSX plate reader and by
digital PCR using probes targeting the RPP30 gene. All
patient and sample details are summarized in Fig. 1b
and Additional file 1: Table S1.
MonReC study sample collection
An independent cohort of patients was recruited to the
Graz based MonReC (monitoring renal cancer) study
(approved by Ethics Committee of the Medical Univer-
sity of Graz, Austria, approval number 27-210 ex 14/15
and by the Ethics Committee of the Military Institute of
Medicine, Warsaw, Poland, approval number 33/WIM/
2015). Written informed consent was obtained from all
patients before blood draw.
For the MonReC study, plasma was obtained at first
diagnosis of metastases, during several lines of treatment,
and/or at every further instance of progression/develop-
ment of new metastases along with the introduction of a
new line of treatment. Patient details are summarized in
Fig. 1c and in Additional file 1: Table S2.
We obtained 49 blood samples from 18 patients
(mean age 62.5 years; range 46–81) from the Depart-
ment of Urology and from the Division of Oncology,
Department of Internal Medicine, at the Medical Univer-
sity of Graz, Austria. In addition, 204 plasma samples
were collected from 25 patients with metastatic disease
(mean age 58.9 years; range 41–68), recruited from the
Department of Oncology at Military Institute of Medicine,
Poland.
For the Graz cohort, 9 ml blood was drawn into
EDTA-containing tubes containing 10% NBF (BD Bio-
sciences) or Streck tubes. Blood drawn at the Medical
University of Graz, Austria (18/43 patients), was imme-
diately sent to the Institute of Human Genetics. Plasma
was extracted as described previously [15] and stored at
− 80 °C prior to analysis. For samples collected at the
Military Institute of Medicine, Poland (25/43 patients),
plasma was extracted there and stored at − 80 °C before
shipping to Graz. cfDNA was extracted from 2ml of
plasma using QIAamp Circulating Nucleic Acid Kit
(QIAGEN) according to the manufacturer’s protocol.
DNA was quantified using Qubit dsDNA HS Assay Kit
(Thermo Fisher Scientific).
Library preparation and exome capture of tissue and
germline samples from DIAMOND patients
In order to identify patient specific somatic mutations,
whole-exome sequencing (WES) of all tumor tissue and
germline buffy coat DNA samples was carried out. Fifty
nanograms of DNA was fragmented by acoustic shearing
(Covaris) according to the manufacturer’s instructions.
Libraries were prepared using the Thruplex DNA-Seq
protocol (Rubicon Genomics) using 5x cycles of PCR.
Exome capture was performed using the TruSeq Exome
Capture protocol (Illumina) with the addition of i5 and
i7 specific blockers (IDT) during the hybridization steps
to prevent adaptor “daisy chaining.” After capture, 8x cy-
cles of PCR were performed. Libraries, before and after
hybrid capture, were quantified using KAPA library
quantification kits (KAPA) and fragment size distributions
were determined using a Bioanalyzer or Tapestation
(Agilent). Sequencing was performed on a HiSeq 4000
(Illumina).
DIAMOND shallow whole-genome sequencing and
trimmed median absolute deviation (tMAD) analysis
Shallow whole-genome sequencing (sWGS) was per-
formed on all tissue, plasma, and urine (USN and UCP)
samples. For each sample type, libraries were pooled in
an equimolar fashion and 150 bp paired end sequencing
was performed (to give an average 16.4 million reads per
sample) using an Illumina HiSeq 4000.
For sWGS analysis, sequence data was analyzed using
an “in-house” pipeline that consists of the following;
paired-end sequence reads were aligned to the human ref-
erence genome (GRCh37) using BWA (version 0.7.13)
[16] after removing any contaminant adapter sequences.
SAMtools (version 1.3.1) [17] was used to convert files to
BAM format. PCR and optical duplicates were marked
using Picard-Tools’ (version 2.2.4) “MarkDuplicates” fea-
ture and these were excluded from downstream analysis
along with reads of low mapping quality and supplemen-
tary alignments.
CNA calling of tissue was performed in R using the
QDNAseq pipeline [18]. Briefly, sequence reads were
allocated into equally sized (here 1Mb and 50 kb) non-
overlapping bins throughout the length of the genome.
Read counts in each bin were corrected to account for
sequence GC content and mappability, and bins corre-
sponding to previously “blacklisted” (ENCODE) and
manually blacklisted regions were excluded from down-
stream analysis.
For all sWGS data, we calculated the trimmed median
absolute deviation (tMAD) from the copy number neu-
tral state. This method is described in detail in Mouliere
et al. [19]. Briefly, this method compares normalized
read counts across genomic bins in cases against those
from a cohort of healthy control samples and the me-
dian absolute deviation from log2R = 0 of segmented
bins is calculated. To define the detection threshold, we
measured the tMAD score for sWGS data from 46
healthy individuals and took the maximal value (me-
dian = 0.01, range 0.004–0.015). The approach has a
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sensitivity of 0.3% [19] and details can be found at its github
page (https://github.com/sdchandra/tMAD). We down-
sampled all plasma bam files to 10 million reads and carried
out analysis using a bin size of 30 kbp. We used two forms
of normalization—(1) normalization to a plasma sample
from a cohort of healthy controls and (2) normalization to
the samples’ own mean logR. All plasma and USN samples
were analyzed by method 1. UCP samples were analyzed by
method 2 as no matched healthy control samples were
available for that sample type. For these UCP samples,
ctDNA was detected if we observed a signal that deviated
from the copy number neutral state.
In order to enrich for tumor-derived cfDNA frag-
ments in plasma, we employed in silico selection of se-
quence reads within particular DNA fragment size
ranges, an approach demonstrated to enrich for mutant
signal in plasma [19]. Here, we downsampled sequence
bam files to 2 million reads and carried out tMAD ana-
lysis using a bin size of 500 kbp. If, after size selection,
sequence bam files had < 2 million reads, they were
considered as ineligible for tMAD analysis. Signal was
normalized against a similarly downsampled cohort of
healthy controls.
MonReC Modified Fast Aneuploidy Screening Test-
Sequencing System (mFAST-SeqS)
In order to estimate the tumor fraction prior to more
expensive genome-wide and/or high-resolution ap-
proaches, all samples collected in Graz were analyzed
using the mFAST-SeqS method. Briefly, this approach is
based on the selective amplification of LINE-1 se-
quences. LINE-1 amplicon libraries were generated from
0.5–1 ng of plasma derived DNA according to our previ-
ously published protocol [20]. Libraries were pooled
equimolarily and sequenced on the Illumina NextSeq or
MiSeq platform generating a minimum of 100,000
single-end reads for each sample. LINE-1 read counts
per chromosome arm and on a genome-wide level were
counted and compared to a set of healthy controls and
deviations were reflected in z-scores [20].
MonReC shallow whole-genome sequencing and
ichorCNA analysis
For a subset of MonReC samples, sWGS was performed.
To this end, shotgun libraries were generated from 5 to
10 ng of plasma DNA using the TruSeq DNA Nano
Sample Preparation Kit (Illumina, San Diego, CA, USA)
as previously described [15]. Libraries were quantified by
qPCR with the quality checked using a Bioanalyzer DNA
7500 Kit (Agilent Technologies). Pooled libraries were
sequenced on the Illumina NextSeq or MiSeq platform
using the 2 x75bp paired-end mode. Additionally, data
were analyzed with the previously published ichorCNA
algorithm to calculate tumor fraction from ultra-low-
pass whole-genome sequencing [21]. Due to the low
tumor fractions, we applied an updated version of the
algorithm (https://github.com/broadinstitute/ichorCNA/
wiki/Parameter-tuning-and-settings). Moreover, in silico
size selection was performed to enrich for tumor-derived
fragments. As the lower limit of detection of ichorCNA
was previously determined as a tumor fraction of 0.03,
samples with tumor fractions below that threshold
were considered as ctDNA negative. Due to the lower
number of reads after size selection, the number of
total reads was also downsampled to enable comparable
profiles and to exclude false positive calls (see Supplemen-
tary material). For samples with less than 2 million reads
after size selection, samples were only considered as
positive when somatic copy number alterations (SCNA)
frequently found in RCC according to the ProGenetix
database were observed.
DIAMOND mutations calling of tissue WES data
Mutation calling of WES data was performed as follows:
Sequence data were aligned with BWA MEM v0.7.15
[22] to the GRCh37/hg19 human reference genome as-
sembly that includes unlocalized and unplaced contigs,
the rCRS mitochondrial sequence (AC:NC_012920), hu-
man herpesvirus 4 type 1 (AC:NC_007605), and the
hs37d5 decoy sequence. Duplicate read pairs based on
aligned positions of each end were marked using Picard
v1.122 (http://broadinstitute.github.io/picard).
We focused our mutation calling efforts on regions of
the genome that had depth > 20× in the matched germ-
line buffy coat sequencing data. For this, we used the
CallableLoci tool from GATK [17]. Somatic mutations
were called using Mutect2 [23]. In addition to Mutect2’s
filters, we applied additional filters described in Add-
itional file 1: Table S3 [24].
We excluded SNVs that represented likely SNPs by
virtue of their having a population allele frequency of
above 0.02 in the 1000 Genomes project global data-
base [25]. Furthermore, we excluded variants that had
an AF > 0 in any normal adjacent tissue samples.
Despite these filters, we observed a large excess of
C:G>A:T mutations in sequencing data from FFPE
samples. We explored features of the artifact that could
be used to distinguish it from true somatic C:G>A:T calls
and found that it had a distinctive sequence context;
specifically, it was often preceded by C or T and G
or A respectively (i.e., [C/T] C>A and [G/A] G>T). As
such we filtered out all C:G>A:T calls that had this
sequence context. The resulting lists of patient-specific
SNVs were used to guide the TAPAS panel design. WES
revealed an average 297.36 unique somatic single nucleo-
tide variants (SNV) per patient that passed our quality
thresholds.
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DIAMOND Tailored Panel Sequencing (TAPAS)—custom
capture panel design based on WES data
A 2.077-Mb (57,306 probes) personalized capture panel
was designed based upon the somatic SNVs identified by
WES of patient FF and FFPE tissue samples. Significant fil-
tering of SNVs was required, as outlined above. The panel
was designed using Agilent’s interactive online design tool,
Sure Design (Agilent). The probe tiling parameters used
were as follows; Tiling density = 1×, Masking =Most strin-
gent, Boosting =Maximize performance, Extension into
repeats = 20, Strand = sense.
As well as targeting the patient specific mutations identi-
fied by WES of patient tumor samples, the open reading
frames of oncogenes and tumor suppressor genes previ-
ously implicated in renal tumorigenesis were tiled. These
included the genes VHL, PBRM1, and SETD2 [2]. The pro-
moter region of TERT was also tiled [26]. The complete list
of genes tiled by the panel is shown in Additional file 1:
Table S4 while all genomic regions targeted for hybrid cap-
ture, as part of the INVAR-TAPAS panel, are provided in
Additional file 2.
DIAMOND fluid library preparation and hybrid capture
Libraries were generated from 15 to 30 ng plasma and
USN derived DNA using Thruplex Tag-Seq kits (Rubicon
Genomics). Tag-Seq libraries contain unique molecular
indexes (UMIs) that make it possible to trace a sequence
read back to the original DNA fragment that yielded it.
After 8–11 PCR cycles (dependent on input), libraries
were quantified using KAPA library quantification kits.
UCP DNA was sheared using acoustic shearing (Covaris)
and 15–30 ng were used for library preparation as above.
333.3 ng each of three libraries was pooled and the
1000 ng mix was used for hybrid capture using the cus-
tom SureSelect XTHS panel described above (Agilent).
Hybridization was carried out with the addition of i5
and i7 specific blockers (IDT). Captured libraries were
amplified using 13 cycles of PCR. Captured libraries were
quantified using KAPA library quantification kits, and
sequenced across multiple HiSeq4000 (paired end 150
bp) lanes such that at least 30 million sequencing reads
were obtained for each sample in order to allow suffi-
cient duplication for the proper use of UMIs.
DIAMOND INVAR-TAPAS ctDNA detection
Aligned sequence reads were “collapsed” using UMI
sequences incorporated during library preparation. The
CONNOR tool (https://github.com/umich-brcf-bioinf/
Connor/blob/master/doc/METHODS.rst) was used, with
the following settings; minimum family size = 2, requires
percent majority = 90%.
We applied our INtegration of VAriant Reads - TAilored
PAnel Sequencing (INVAR-TAPAS) approach to the
custom capture sequence data (Additional file 1: Fig. S2).
Briefly, the INVAR algorithm [27] aggregates signal across
hundreds to thousands of mutant loci identified by WES
and targeted by the custom capture panel (described
above). Error suppression, through the use of UMIs, and
consideration of mutation sequence context, fragment
length, and tumor mutant allele fraction is used to dimin-
ish background noise levels and enrich for ctDNA signal.
This generates a significance level for each of the patient
specific loci, which are combined into an aggregate likeli-
hood function. Sequencing data from DNA of patients
using non-matched mutation lists are used as negative
controls for receiver operating characteristic curve analysis
to select a likelihood threshold for ctDNA detection. A
global ctDNA allele fraction is determined by taking a
background-subtracted, depth-weighted mean allele frac-
tion across the patient-specific loci in that sample.
The sensitivity of ctDNA detection depends on the
total number of informative reads (IR; unique molecules
aligning to patient specific mutant loci) covering tumor-
mutated loci. Samples with < 20,000 IR will have limited
ability to detect ctDNA. Few IR can be the results of too
few patient-specific mutations detected in tissue (< 100
mutations). In these situations, detection to levels below
1.0 × 10− 4 mAF would require re-analysis using greater
amounts of input DNA and/or re-design of the capture
panel targeting a greater number of patient specific
mutations. As such, those samples with too few IR were
excluded as technical failures.
MonReC QIASeq custom panel sequencing
For mutation profiling, a customized QIAseq Targeted
DNA Panel (CDHS-11685Z-538; QIAGEN) was used.
The panel enriches 10 genes that are frequently mutated
in RCC: BAP1, KDM5C, MET, MTOR, PBRM1, PIK3CA,
PTEN, SETD2, TP53, VHL. Libraries were prepared from
10 ng plasma DNA according to the QIAseq targeted
DNA Panel Handbook (R2). Briefly, the DNA template
was enzymatically fragmented, end-repaired, and A-
tailed. Each DNA molecule was then tagged using an
Illumina-specific adapter containing a UMI. Target re-
gions were enriched by one target-specific primer and
one universal primer. Finally, library amplification and
completion of Illumina adapters was done in a universal
PCR with 18 cycles. Libraries were quantified using the
QIAseq Library Quant Assay (QIAGEN), and the frag-
ment size was checked using the Bioanalyzer High Sensi-
tivity DNA Kit (Agilent Technologies). Libraries were
pooled equimolarily and sequenced on the Illumina
NextSeq platform. On average, 3.47 million reads
(range 1.33–5.7 M) were obtained per sample. Raw
sequencing data generated by the QIAseq Targeted
DNA Panel was analyzed using the QIAseq targeted
DNA Panel Analysis pipeline, which processes the UMI
information to distinguish between true variants and
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sequencing errors based on smCounter V1 [28]. All
variants that did not pass the predefined quality criteria
from smCounter were dismissed. Moreover, we filtered
synonymous variants and variants present with minor
allele frequencies of > 1% in population frequency data-
bases (ExAC, gnomAS, 1000 g, TOPMED) were consid-
ered as polymorphisms. In order to increase variant
calling stringency, we analyzed all samples in duplicate
(median raw sequencing depth 9688.3, range 4176.7-
17043.9), and only considered variants to be real if
identified in both replicates. All detected variants were
visually checked using Integrative Genomics Viewer
(IGV) (version 2.3.58). Sensitivity assessment of two in-
dependent dilution series using SeraCare reference ma-
terial revealed detection rates of 90% and 100% for 0.02
mAF, 70% for 0.01, and 25% for 5.0 × 10− 3 based on
the evaluation of 10 different mutations. Variants with
an expected mAF of 2.5 × 10− 3 and 1.3 × 10− 3 could
not be detected.
ctDNA detection and comparison against patient tumor
size and presence of renal vein or inferior vena cava
tumor thrombus
For DIAMOND patients, we assessed whether there
was a difference in the distribution of tumor sizes
amongst patients with detected ctDNA as compared
to those in whom ctDNA was not detected. Tumor
size was determined as the maximum diameter of the
primary tumor on abdominal CT scan. We deter-
mined whether there was a relationship through the
use of Mann-Whitney’s U test.
Similarly, we compared ctDNA detection in patients
displaying evidence of extension of a tumor thrombus
into the renal vein or inferior vena cava, as assessed on
cross-sectional imaging, with those that did not have a
tumor thrombus. Fisher’s exact test was used to deter-
mine associations between detection of ctDNA (in indi-
vidual and combined fluids, by INVAR-TAPAS +/−
tMAD) and tumor thrombus extension, with a signifi-
cance threshold of p < 0.05.
In both cases, these were exploratory analyses, and to
confirm the corresponding findings and hypotheses,
further confirmatory tests are required.
Ki-67 staining of DIAMOND tissue
We compared ctDNA detection with the Ki67 cellular
proliferation rate in matched tumor cells, as levels of
Ki67 have previously been found to correlate well with
levels of ctDNA [29]. We carried out immunohisto-
chemical (IHC) staining of FFPE tissue sections from a
subset of DIAMOND patients, using an anti-Ki67 mono-
clonal antibody (MIB-1 clone at 1:100 dilution; DAKO
Agilent Technologies LDA). The immunohistochemistry
was scored manually at × 400 magnification. For each
slide, 20 separate high-powered fields were assessed for
positively stained tumor cell nuclei by a specialist uro-
pathologist (AYW). Across the 20 regions, at least 6000
tumor cells were studied for each patient. An arbitrary pro-
portion score was used to assess Ki67 levels with regions
containing up to 0%, 1%, 10%, 30%, 75%, and 100% of posi-
tive cells being assigned a score of 0, 1, 2, 3, 4, and 5 re-
spectively. The sum of these scores, across all 20 regions,
was used as an indicator of the level of proliferation.
These values were subsequently compared between
patients with detected and no-detected ctDNA with T-
test p < 0.05 indicating a significant difference.
Random forest model for ctDNA detection prediction
The model used here was based upon a classification model
described in Mouliere et al. [19]. Briefly, the model con-
siders the following fragmentation features (outlined in de-
tail in the referenced manuscript) which were calculated
from sWGS data: t-MAD, amplitude_10bp (the amplitude
of 10 bp oscillations), P(20–150) (the proportion of frag-
ments between 20 and 150 bp), P(160–180), P(20–150)/
P(160–180), P(100–150), P(100–150)/P(163–169), P(180–
220), P(250–320), P(20–150)/P(180–220). The model was
trained using sWGS data from a cohort of “high ctDNA”
cancer samples and was validated on “low ctDNA” cancer
samples, including plasma from the sub-cohort of DIA-
MOND patients used in this study. Optimal classification
of samples from cancer patients and controls was observed
using a random forest (RF) machine-learning algorithm.
Here, we used the RF disease classification model to tri-
age patient samples, predicting which RCC patients were
likely to have sufficient ctDNA (in plasma or urine) for
targeted sequencing by other, more sensitive, methods.
We used “50% probability of cancer classification” as a
threshold, comparing ctDNA detection amongst patients
that fell above and below this value, as output by the RF
model. We compared the ability of the model to triage pa-
tients using the INVAR-TAPAS method with or without
tMAD in plasma alone, or in either fluid.
Assessment of tumor heterogeneity and representation in
plasma and urine
We assessed the heterogeneity of tumor samples from
patient 5842, and its representation in plasma and urine
samples obtained prior to nephrectomy. Mutations in
tissue were called as described above. The SAMtools
(version 1.3.1) [17] function mpileup was used to assess
allelic content at mutant loci, with a mAF calculated for
each site and this data was converted to a matrix. A
heatmap was generated from this data using the R heat-
map function. Hierarchical clustering was by mutations
(columns) but not by sample (rows) according to Euclid-
ean distance.
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Results
Untargeted analysis of ctDNA in plasma and urine from
patients with renal tumors
We applied a combination of rapid and cost-effective
untargeted approaches, albeit with limited sensitivity, to
establish a first measure of ctDNA presence and levels
in patients with benign through to metastatic disease
(n = 91 patients from the DIAMOND and MonReC
studies; patient characteristics are shown in Fig. 1a–c
and Additional file 1: Table S1-S2). In DIAMOND, pa-
tient plasma and urine were collected prior to partial or
radical nephrectomy. In MonReC, the majority of
patients had plasma collected during treatment for re-
current disease (mean time between first blood draw
and surgery, 48 months, range 0–269). First, we assessed
overall ctDNA levels using the trimmed median absolute
deviation (tMAD) score calculated from shallow whole-
genome sequencing (sWGS) [19] of plasma from 48
DIAMOND patients (Fig. 1b). As this method is
dependent on the presence of SCNA, we applied sWGS/
tMAD to matched tumor tissue, available from 28 of 48
patients (58.3%). All had SCNA (Additional file 1: Fig. S3),
suggesting that SCNA are a valid ctDNA target in pa-
tients. However, in plasma, we detected SCNA in only 3
of 48 (6.3%) patient samples (Fig. 2a, one patient with
metastatic ccRCC and 2 with non-metastatic chRCCs).
Next, we employed in silico selection of sequence
reads within particular DNA fragment size ranges, an
approach demonstrated to enrich for mutant signal in
plasma [19, 30]. After selection of reads between 90 and
150 bp, 41/48 plasma samples from DIAMOND met the
criteria for evaluation by tMAD analysis (> 2 million
reads) (Additional file 1: Fig. S4A). On average, tMAD
scores increased 2.2-fold (range 1.25–4.83) and led to
ctDNA detection in 8 additional patients (Fig. 2a) in-
cluding a patient with an oncocytoma (Additional file 1:
Fig. S5A). Thus, in total, we detected plasma ctDNA in
11/48 (22.9%) DIAMOND patients.
Fig. 2 ctDNA detection using untargeted assays. a Distribution of tMAD scores across DIAMOND plasma samples (x-axis). Data points are colored
according to disease subtype. A tMAD score of > 0.015 (gray dashed line) indicates SCNA, and thus ctDNA. ctDNA was detected in 3/48 (6.3%)
plasma samples. Data on the y-axis show tMAD scores for the same plasma samples after in silico size selection for sequencing reads 90–150 bp
in length. On average, the tMAD score increased 2.2-fold (range 1.25–4.83) and led to ctDNA detection in 8 additional patient samples, resulting
in ctDNA detection in 11/48 (22.9%) DIAMOND patients. Four patient samples had insufficient sequencing reads after size selection for tMAD
analysis (red highlight). b Tumor fraction of MonReC ctDNA-positive plasma samples (n = 14), as calculated by ichorCNA, before and after in silico
size selection for sequencing reads 90–150 bp in length. On average, tumor fraction increased 2.2-fold (range 0.9–5.7) and revealed six patients
with detected ctDNA, in addition to the eight patient samples detected without size selection. c Plot showing distribution of tMAD scores across
DIAMOND plasma (no size selection), urine supernatant (USN), and urine cell pellet (UCP) samples. Samples from the same patient are connected
by gray lines. The detection threshold is indicated by a red dashed line. d tMAD and e z-score distribution of RCC samples were compared to
samples from other cancer types collected at the University of Cambridge [19] and Medical University of Graz respectively. Renal samples are
highlighted. GBM = glioblastoma, Mel = melanoma, ChC = cholangiocarcinoma, CRC = colorectal cancer. A similar comparison was carried out
using the ichorCNA metric (Additional file 1: Fig. S7C)
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The MonReC cohort consisted primarily of metastatic pa-
tients (two non-metastatic), most with their primary tumor
removed (35/43 patients) (Fig. 1c). Samples were initially an-
alyzed with untargeted methods, mFAST-SeqS [20] and
sWGS (ichorCNA tumor fraction) (Additional file 1: Table
S5). A mFAST-SeqS z-score of ≥ 3 indicates tumor fractions
of > 3–10% (depending on the number and amplitude of
SCNA) [31]. At baseline, z-scores ranged from − 0.6–3.7
(median = 0.7) with only 2/43 patients (4.7%) surpassing the
detection threshold. The ichorCNA algorithm [21] revealed
six further patients with detected ctDNA (8/43 = 18.6%;
Fig. 2b) with tumor fractions up to 0.17 (median 0.07, range
0.04–0.17). As above, in silico size selection further
improved the ichorCNA detection rate to 14/43 (32.6%)
(Fig. 2b, Additional file 1: Fig. S6 and 7). On average, tumor
fraction from ctDNA positive samples increased 2.2-fold
(range 0.9–5.7) to a median of 0.08 (range 0.04–0.23). To
assess the impact of size selection and the accompanying
decrease of signal-to-noise ratio, we randomly downsampled
the initial sequence data to a read count equivalent to that
attained after size selection, and also analyzed a set of
healthy controls. Despite finding that the proportion of
small fragments (< 90–150 bp) in controls was much lower
than in RCC samples (3.8% versus 7.8% of total reads) which
in-turn led to a higher background, RCC-specific SCNA
such as loss of 3p or 8p and gain of 3q or 8q were observed
in none of the control samples.
As sampling of biofluids collected in close proximity
to the tumor site may improve detection [14, 32], we
analyzed urine supernatant (USN) samples from 37 DIA-
MOND cohort patients. Applying tMAD to USN for the
first time (Additional file 1: Fig. S4B), ctDNA was detected
in 8 patients (21.6%) (Fig. 2c, Additional file 1: Fig. S4C),
including six patients with ccRCC, a patient with oncocy-
toma (not detected in plasma, Additional file 1: Fig. S5B),
and a patient with MiT family translocation RCC. In
addition to USN, we had access to urine cell pellet (UCP)
DNA for 21 patients. UCP DNA is not cell-free but allows
non-invasive detection of tumor DNA [14, 33]. UCP
tMAD analysis revealed 3/20 (15%) patients with detected
ctDNA, including one with localized ccRCC, the largest
tumor of the cohort with a diameter of 23 cm. Compari-
son of plasma, USN and UCP data did not reveal a clear
relationship in detection amongst these compartments
(Fig. 2c, Additional file 1: Fig. S4C), confirming previous
observations in bladder cancer [14, 34]. Considering only
those patients for which we had access to plasma
and urine, the detection rate increased to 16/37 (43.2%). Of
note, two patients (including 5842 and 7092, Additional file 1:
Table S1) had detected ctDNA in both plasma and urine.
Overall, untargeted sequencing methods employed here
suggested low ctDNA detection rates in plasma and/or
urine of patients with renal tumors (19/48, 39.6% in DIA-
MOND, 14/43, 33% in MonReC). Even in metastatic
disease, the detection rate was only 35.4% (MonReC 13/41,
DIAMOND 4/7). Comparison of plasma ctDNA levels, as
quantified by tMAD, mFAST-SeqS, and ichorCNA, against
other cancer types confirmed that ctDNA levels are lower
in renal tumors (Fig. 2d, e, Additional file 1: Fig. S7C).
Parallel analysis of urine (USN and UCP) also revealed low
detection rates. ctDNA was detected in either fluid in
patients with a range of tumor subtypes including, unex-
pectedly, patients with benign oncocytoma. Given these
low detection rates, we hypothesized that techniques with
greater sensitivity were required to quantify ctDNA in renal
tumors.
Targeted analysis of ctDNA yields improved detection rates
For DIAMOND patients, INtegration of VAriant Reads –
TAilored PAnel Sequencing (INVAR-TAPAS) was used, an
approach demonstrated to detect plasma ctDNA to parts
per million [27] (Additional file 1: Fig. S2). This method re-
lies on a priori knowledge of tumor specific mutations and
thus, for 29 DIAMOND patients, we carried out whole-
exome sequencing (WES) of matched tumor tissue and
buffy coat (Additional file 1: Fig. S8). We observed exten-
sive disease heterogeneity as previously described [2, 4]
(Additional file 1: Fig. S9). Patient-specific mutations of key
RCC genes are listed in Additional file 1: Table S6. A per-
sonalized capture panel was designed targeting all
patient-specific SNV from tissue WES as well as the
coding regions of 109 genes commonly mutated in
renal tumors (Additional file 1: Table S4). Based on the
requirements of the INVAR algorithm, seven plasma
samples (7/29, 24.1%) had insufficient reads, resulting in
limited ability to detect ctDNA, and were thus excluded as
technical failures (Additional file 1: Fig. S10A).
In the 22 remaining plasma samples, ctDNA was
detected in 12 (54.5%) (Fig. 3a). Ten of these (83.3%)
were ccRCC samples, including three detected by tMAD
analysis of sWGS data. It is noteworthy that 9 of these
patients had the largest evaluable ccRCC tumors in the
cohort (7.4–23 cm). However, ctDNA was also detected
in a patient with a small (2.8 cm) ccRCC with global mu-
tant allele fraction, gmAF = 6.4 × 10− 5. Of the remaining
patients with detected ctDNA, one had a small chRCC
(2 cm) with gmAF 1.8 × 10− 4, and the other had a benign
oncocytoma (3.9 cm) with gmAF of 2.7 × 10− 4. Assess-
ment of all tumor subtypes revealed a significant (p =
0.02, Mann-Whitney’s U test) correlation between
ctDNA detection and tumor size (Fig. 3b, Add-
itional file 1: Fig. S11A). Similarly, ctDNA detection
was more likely in patients with locally advanced
RCC denoted by renal vein or inferior vena cava
tumor thrombus (p < 0.05 for detection by INVAR-
TAPAS +/− tMAD, Fisher’s exact test; Fig. 3c, Add-
itional file 1: Fig. S12A-C). Conversely, Ki-67 assessed
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cellular proliferation rate did not correlate with detec-
tion (Additional file 1: Fig. S12D-F).
For the first time, we applied INVAR-TAPAS to USN
from 20 patients. As in plasma, six samples (30%) had in-
sufficient sequence reads and were excluded as technical
fails. We detected ctDNA in USN of 7/14 patient samples
(50%) (Fig. 3d; ccRCC n = 5, chRCC n = 1, oncocytoma n =
1). Two of these patients had detected urine ctDNA by
tMAD analysis, while four had detected ctDNA in plasma
(by INVAR-TAPAS or tMAD). Of note, the oncocytoma
patient (histology confirmed; Additional file 1: Fig. S13) had
ctDNA detected in plasma (gmAF USN 5.7 × 10− 5 vs
plasma 2.7 × 10− 4). In contrast to plasma, there was
no correlation between USN ctDNA detection and le-
sion size across all patients (Additional file 1: Fig.
S11B), venous tumor thrombus invasion (Fig. 1b and
Fig. 3c, Additional file 1: Fig. S12A-C) or proliferation
rate (Additional file 1: Fig. S12D-F). There was no
correlation between the global ctDNA mAF in plasma
and urine (Spearman’s rho = 0.28, p = 0.3; Fig. 3e),
though in the majority of patients, levels proved too
low for accurate quantification of tumor fraction.
For metastatic RCC patients recruited to MonReC,
no tumor tissue was available and so a de novo muta-
tion calling approach was applied to plasma DNA. A
gene panel targeting ten significantly mutated genes in
renal cancers (BAP1, KDM5C, MET, MTOR, PBRM1,
PIK3CA, PTEN, SETD2, TP53, VHL) [35] was used
with a maximal achievable sensitivity of 5 × 10− 3 mAF.
Based on existing data, one would expect a somatic
mutation to be present in > 80% of metastatic ccRCC
patients in at least one of these genes [36]. However,
ctDNA was detected in only 8/43 (18.6%) baseline
samples (Fig. 3f, Additional file 1: Table S5, S7).
mAF ranged from 3.5 × 10− 2–0.18 with an average of
8.3 × 10− 2. Except for patient K42 (Fig. 1c), SCNA
were detected in all of these samples after size selection.
SETD2 was the most frequently mutated gene in the
cohort with a mutation being observed in 4 of the 8
mutation-positive patients (50%). KDM5C, PBRM1, and
VHL were the next most frequently mutated genes with
mutations being observed in 2/8 (25%) in both instances
(Fig. 1c). In four patients, two or more mutations were
identified.
We sought to identify whether untargeted plasma
sWGS data could predict which patients would be suitable
for downstream INVAR-TAPAS analysis, by application
of a random forest model that considers fragmentation
features of cfDNA (Additional file 1: Fig. S14A) to classify
patient samples as healthy vs cancerous [19]. The model
predicted detection of ctDNA by INVAR-TAPAS in
plasma and/or urine in 91.7% of DIAMOND patients
with an RF model score of > 50% vs. 36.4% of patients
with an output < 50% (p = 9.4 × 10–3 Fisher’s exact
test) (Additional file 1: Fig. S14). This data highlights
the potential of the use of cost-effective techniques to
triage patient samples for subsequent analysis by
more expensive and time-consuming methods.
Fig. 3 ctDNA detection using targeted assays. a Application of INVAR-TAPAS to DIAMOND plasma samples. ctDNA was detected in
plasma of 12/22 (54.5%) patients, with global ctDNA mAF (gmAF) shown on the y-axis. Disease subtype is indicated by bar color, see
insert for figure legend. b Assessment of the correlation between primary tumor size (diameter, cm), and ctDNA detection. Detection was
via tMAD and/or INVAR-TAPAS, and in either fluid. This observation was driven by plasma (Additional file 1: Fig. S11A) with no apparent
relationship in urine (Additional file 1: Fig. S11B). c ctDNA detection in plasma by INVAR-TAPAS was significantly more frequent amongst
patients with venous tumor thrombus as compared to those without. This was not the case when considering ctDNA in urine or ctDNA
in either fluid (Additional file 1: Fig. S12A-C). d INVAR-TAPAS was applied to DIAMOND USN samples. ctDNA was detected in 7/14 (50%)
patients. e Comparison of gmAF of plasma and USN samples. In patients for whom we had access to both fluids, lines connect data
points (Spearman’s rho = 0.28, p = 0.3). f Summary of targeted sequence analysis using a 10-gene QIASeq panel. Mutations at baseline
were detected in 8/43 (18.6%) MonReC plasma samples. The y-axis denotes mAF which ranged from 3.5 × 10−2–0.15 (if two or more
mutations were detected, the mean was calculated)
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However, the numbers of patient samples were small
and independent validation of these findings is
required.
ctDNA detection across all patient samples are summa-
rized in Fig. 4 and Additional file 1: Fig. S15. Targeted
analysis with a personalized approach (INVAR-TAPAS)
improved ctDNA detection over untargeted analysis.
Overall (targeted and untargeted data), 27 of 48 (56.3%)
DIAMOND patients had detected ctDNA, whether in
plasma or urine, though not all patient samples had the
Fig. 4 Summary of ctDNA detection in all patients and all biofluids. a Summary of ctDNA detection in baseline plasma (left of triangle box pair) and
urine (right of pair) of DIAMOND ccRCC (left), chRCC (top right), and oncocytoma (oncoC, middle right) patients. Four patients with “other” disease
subtypes are also shown (“other,” bottom right). Samples are ranked in descending order according to tumor size (cm). For each data point, the upper
left triangle shows the results of INVAR-TAPAS analysis and the bottom right the results of tMAD analysis. Green triangles indicate samples in which
ctDNA was detected, white triangles indicate samples in which ctDNA was not detected, gray triangles indicate no data available (because the assay
was not applied to that sample, or no sample was available), and pink triangles indicate failed assay. Data points with a black outline indicate patients
with metastatic disease at the time of sampling. DIAMOND patients 5842 and 5634 (longitudinal section) are highlighted with an orange box. b
Summary of ctDNA detection in baseline (left of triangle box pair) and follow-up (right of pair) plasma of MonReC patients. Each subtype is shown in a
separate box (ccRCC, clear cell; pRCC, papillary; chRCC, chromophobe; NA, unknown). The upper left triangle shows the results of QIASeq analysis, the
bottom right the results of ichorCNA analysis. Triangle color, as above. Forty-one patients had metastatic disease and, where data was available, the
number of metastatic sites is indicated. ctDNA detection are plotted alongside patient characteristics in Additional file 1: Fig. S15
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most sensitive approach applied to them or had both
plasma and urine available. Of those that did, 11/13
(84.6%) patients had ctDNA detected. Of note, only one
patient (5842) had ctDNA detected in both plasma and
urine by both untargeted and targeted methods. For the
MonReC cohort, the overall ctDNA detection rate of
34.5% was lower than for DIAMOND, most likely due to
the use of less-sensitive de novo methods. Taken together,
ctDNA detection in plasma and urine is challenging in
patients with renal tumors, with tumor size (Fig. 3b) and
renal vein or inferior vena cava tumor thrombus locally
advanced disease (Fig. 3c) being the single greatest factors
contributing to detection (as assessed in DIAMOND,
Additional file 1: Fig. S11, S12A-C).
Longitudinal analysis of ctDNA in renal tumors
An aim of the MonReC study was to investigate the poten-
tial of plasma ctDNA to monitor treatment response in
metastatic RCC, as such we had access to longitudinal
plasma samples for 37/43 (86%) MonReC patients. During a
median follow-up period of 6months (range 0.4–19.2), serial
plasma samples (median 5, range 2–21) were collected
before and during treatment. mFAST-SeqS was used as an
initial measure of tumor content [20, 37]. For all samples,
the median genome-wide z-score was 1.0 (range − 0.9–58.0),
and an elevated z-score was observed in 19/252 samples
(7.5%) from 9 patients. In those samples, SCNA profiling
revealed expected RCC aberrations, including 3p loss. Using
a linear mixed model with a random intercept at the patient
level, we found significant differences between baseline and
treatment (Wald test, p < 0.001) and progression (Wald test,
p= 0.0294) (Additional file 1: Fig. S16). Longitudinal muta-
tion analysis was performed in 14 patients. Of those, 6 pa-
tients (K18, K20, K23, K27, K39, K42) had mutations called
at baseline (Fig. 5a–c, Additional file 1: Fig. S17). Due to low
detection rates at baseline, we analyzed additional samples
whose collection coincided with clinical progression and
identified three further patients (K11, K21, K35) with de-
tected ctDNA. Moreover, ichorCNA was applied to
available follow-up samples of 5 patients (K08, K13, K19,
K40, K44) with detected ctDNA at baseline (Additional file 3:
Table S8). For most patients, ctDNA levels assessed
either by the QIASeq panel or ichorCNA were elevated
at treatment initiation but decreased with response
(Fig. 5b, Additional file 1: Fig. S17A-G). At progression,
or when a treatment response was not gained, ctDNA
increased or remained elevated (Fig. 5c, Additional file 1:
Fig. S17A-G). For example, patient (K39) showed high
levels of tumor DNA (> 0.1 mAF) at all available time
points and died 2.8 months after the first blood draw,
mirroring the rapidly progressing disease (Fig. 5c).
We obtained longitudinal plasma and urine from two DIA-
MOND patients (highlighted in Fig. 4 and Additional file 1:
Fig. S1). Data are summarized in Additional file 1: Fig.
S18–20. ctDNA levels largely fluctuated in accordance
with clinical response as determined by standard imaging.
Of note, the data from one patient highlighted that the de-
tection of ctDNA (9.5 × 10− 4 gmAF) 53 days after radical
nephrectomy pre-empted CT scan detection of minimal
residual disease 82 days after surgery (Fig. 5d and Add-
itional file 1: Fig. S1).
Representation of tumor heterogeneity in plasma and urine
For all but two DIAMOND patients, the low ctDNA levels
precluded meaningful assessment of representation of
tumor heterogeneity in fluid samples. For DIAMOND pa-
tient 5842, we carried out WES of 10 spatially distinct
tumor biopsies obtained after nephrectomy (Additional file 1:
Fig. S21), identifying somatic mutations with varying appar-
ent clonality. We compared the number of regions a muta-
tion was called in, against the mAF of that mutation in
plasma, urine, and tissue (Fig. 5e and Additional file 1: Fig.
S22) and observed an incrementally rising mAF as more
tumor regions were considered (Wilcoxon T-test p < 0.05).
We assessed whether private mutations from each tumor
region were represented in plasma and USN and found that
both overcame this apparent heterogeneity with 90% and
100% of regions represented by at least one mutation in
plasma and urine respectively (Fig. 5f and Additional file 1:
Fig. S23). There was no evidence of one or more tumor re-
gions having greater representation in fluids than others
(Additional file 1: Fig. S24). These data confirm that plasma
ctDNA can overcome tumor heterogeneity [38] and, for the
first time, demonstrates that USN ctDNA is capable of the
same (Fig. 5f). The ctDNA mAF varied between plasma
and urine (mean mAF of detected mutations = 2.2 × 10− 2
vs 1.2 × 10− 2 respectively), with differing representation of
likely driver genes including VHL (ENST00000256474.2:
c.333_340+1delCTACCGAGG) (Additional file 1: Fig. S25).
In patient 5634, plasma showed a similar ability to over-
come heterogeneity with private clusters of mutations all
represented in baseline plasma (Additional file 1: Fig. S26).
Discussion
Here we present the most comprehensive assessment of
ctDNA in renal tumor patients to date, using several
state-of-the-art approaches applied to tissue and liquid
biopsy samples from two independent, prospective clin-
ical cohorts. These cohorts were complementary: (a)
DIAMOND represented patients with the full range of
renal tumors from benign to locally advanced and meta-
static patients and (b) MonReC evaluated metastatic
RCC patients treated with multiple systemic therapies
and longitudinal follow-up/biosampling allowing the
predictive ability of ctDNA to be assessed. We sought to
take a bottom-up approach to determine if inexpensive,
untargeted liquid biopsy approaches could be applied to
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RCC, as they have been successfully employed in breast
[39], colorectal [40] and prostate cancer [41]. These
methods enabled ctDNA detection in 30–40% of pa-
tients with RCC. Even in metastatic patients these
methods achieved only moderate detection rates indicat-
ing generally low levels of tumor-derived DNA.
Personalized high-resolution methods, which are more
expensive, were used with incremental success.
RCC is often an aggressive, angiogenesis-driven ma-
lignancy, in a vascular organ with frequent cellular
necrosis. As such, it is surprising that we observed
such low ctDNA levels. Our data suggest that the
Fig. 5 (See legend on next page.)
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probability of detecting ctDNA rises with increasing
size of the primary tumor. Furthermore, amongst pa-
tients with locally advanced tumor growth, such as
growth of a tumor thrombus into the renal vein or
inferior vena cava, ctDNA detection in plasma, but
not urine, was significantly more frequent. In con-
trast, tumor proliferation rate did not predict ctDNA
detection as observed in patient-derived xenograft
models [42] and lung cancer [29]. Surprisingly ctDNA
detection was also limited to approximately a third of
patients with metastatic disease from the MonReC co-
hort, albeit with substantially higher tumor fractions
than observed in DIAMOND. An initial aim of this
project was to determine the predictive ability of
ctDNA in plasma and urine. Unfortunately, our ability
to assess this was impacted by the low levels and
detection rates of ctDNA in RCC. Nonetheless, we
have attempted to correlate ctDNA levels with disease
course that included several rounds of a variety of
treatments.
There is little published data characterizing ctDNA
levels in RCC. Initial studies suggested low detection rates
and/or levels of ctDNA in locally advanced and metastatic
RCC. More recently, targeted sequencing detected ctDNA
in 30% of 53 RCC patients [10]. Conversely, Pal and col-
leagues detected ctDNA in 78.6% of 200 metastatic pa-
tients using the Guardant360 plasma assay (Guardant
Health), though with a median of one genomic alteration
per sample [43]. The same authors detected ctDNA in a
further 18/34 (53%) metastatic RCC patients and, as
echoed by our data, observed a possible correlation be-
tween detection and lesion diameter [44]. Likely reasons
for the lower detection rate amongst metastatic patients in
the MonReC cohort include our use of a smaller gene
panel which has a detection limit of 5.0 × 10− 3 as com-
pared to 2.0 × 10− 4 for Guardant360. Moreover, their
study analyzed more than 70 RCC associated genes, in-
cluding EGFR, NF1, and ARID1A, many of which were
not included in our assay. Of note, neither of these two
studies reported the range of detected mAFs, meaning
that a direct comparison with our data was not possible.
Nevertheless, the use of larger gene panels, or personal-
ized assays such as INVAR-TAPAS, is likely to increase
ctDNA detection rates. Considered with our data, it is
clear that a consensus concerning ctDNA levels in RCC
has yet to be reached.
For select DIAMOND patients, we also assessed tumor
DNA content in urine (supernatant and cell-pellet) and
found similar levels and detection rates with minimal
overlap between fluids, with only seven patients having
detected ctDNA in both plasma and urine. This data
suggests that the mechanisms that determine the release
and levels of ctDNA in plasma and urine of patients with
renal tumors vary, a finding that requires further mech-
anistic analysis. In particular, it will be important to
evaluate urine samples from patients with metastatic dis-
ease (of which we had only a single case in this study),
to compare the representation of ctDNA in plasma vs.
urine in patients without their primary disease in situ.
We further aimed to assess intratumoral heterogen-
eity through the comparison of multi-region sampled
tumor tissue and ctDNA. Unfortunately, analysis of
further patients was hampered by their low ctDNA
levels. Nevertheless, analysis of two well characterized
DIAMOND patients revealed that mutations from the
majority of sampled tumor regions were detected in
plasma. In addition, we show for the first time that
genetic heterogeneity is represented in ctDNA from
urine. As such, while limited, our data suggest that
ctDNA analysis of both fluids has the potential to
overcome intratumoral heterogeneity that is prevalent
in renal cancers [2].
(See figure on previous page.)
Fig. 5 Longitudinal ctDNA analysis and assessment of intratumoral heterogeneity in plasma and urine. a Longitudinal cfDNA assessment of MonReC
patients with metastatic RCC. Shown are disease courses of patients who had detected ctDNA with QIASeq and/or ichorCNA analysis. Time between
nephrectomy and first blood draw is indicated in days (NA, not available; NN, no nephrectomy). Type and duration of treatment (mTOR =mTOR
inhibitor; PAZ = pazopanib, SUN = sunitinib; EVE = everolimus; CAB = cabozantinib; AXI = axitinib; SOR = sorafenib; IMT = immune therapy) are indicated
by colored lines. Most patients had detected ctDNA at progression (PD), whereas during stable disease (SD) or response (partial response, PR) ctDNA
was undetected. b, c Plots demonstrating dynamic changes in ctDNA in longitudinal plasma from MonReC patients K27 and K39 respectively. Further
details and patient specific plots are in Additional file 1: Fig. S17. d tMAD (left y-axis) and INVAR-TAPAS (right) analysis of plasma taken throughout the
clinical course of DIAMOND patient 5842. Following nephrectomy (scan a; orange arrow= right renal tumor, red arrow = tumor thrombus), while
INVAR-TAPAS global ctDNA levels (black line) drop, it remains detected (gmAF = 9.5 × 10–4) at day 53, indicating residual disease. Conversely, imaging
did not detect residual disease at day 16 (b; normal renal fossa). ctDNA levels rise with disease spread, before falling again upon the commencement
of radio- and chemotherapy. Of note, ctDNA levels continue to fall despite evidence of clinical progression. Further details are provided in
Additional file 1: Fig. S18A-B. tMAD values before (blue line) and after (red line, gray circles = detected ctDNA) size selection are shown. Urine data are
shown in Additional file 1: Fig. S18C. e Comparison of baseline ctDNA mAF in plasma (red) and USN (blue) and the number of tumor regions that
mutation was observed in after multi-region sampling of 5842. *indicates significant difference as compared to mutations detected in just one region.
f Heatmap of mutations detected across 10 tumor biopsies (T1–T9 = fresh frozen, A7 = FFPE) and baseline fluid samples from 5842, with vertical
colored lines indicating individual SNVs. Hierarchical clustering was by mutation according to Euclidean distance. Color intensity corresponds to
mutation mAF. While mutations show different representation in pre-surgery fluids (Additional file 1: Fig. S23), all mutation clusters, even those private
to individual regions, are represented by at least one mutation in plasma and urine (Additional file 1: Fig. S24)
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We also found that ctDNA can indicate minimal re-
sidual disease after nephrectomy (in one case pre-
empting detection by imaging by 29 days), as well as
disease progression on systemic therapies. Another
noteworthy finding was the detection of ctDNA in
the plasma and urine of patients with benign oncocy-
tomas and early-stage ccRCCs. For the former, this is
particularly surprising given the benign nature of
these lesions. While differentiation of small renal
masses into ccRCC, chRCC, or oncocytoma can be
challenging using renal tumor biopsy, these data hint
at the possibility of non-invasively differentiating
small renal masses to guide decisions over invasive
surgery versus active surveillance.
We recognize the limitations of our study. By includ-
ing a broad range of renal mass patients, there was a
limited number of patients with each disease stage. Fur-
thermore, our pre-analytical knowledge evolved during
recruitment to the DIAMOND cohort meaning not all
sample types and time points were available for all pa-
tients. Indeed, due to the low detection rates, longitu-
dinal monitoring was applicable in only a minority of
patients. Moreover, different techniques were applied to
different patient cohorts, though this in turn reinforces
the general statement that ctDNA in RCC is challenging
and further developments are needed for clinical utility.
In future work, standardization of timing of blood draws
especially in relation to systemic therapy dosing requires
further study. Furthermore, larger studies of ctDNA in
ccRCC are now required to better determine its clinical
utility and validate any prognostic or predictive utility.
Beyond this, assays that target multiple biomarkers, in-
cluding proteins [45] and methylated cfDNA [46], will
improve sensitivity for detecting and interpreting tumor
signal. Multiple questions remain about this ctDNA-low
malignancy but there is no doubt that further study is
warranted and will inform approaches for other ctDNA-
low tumor types.
Conclusions
Our data highlight RCC as a ctDNA-low malignancy.
However, we illustrate potential clinical utility for the
management of patients with RCC. Further advances in
pre-analytical and analytical processes, for both urine
and plasma, are needed for this potential to be fulfilled.
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